Chapter 129 Thoughts (Additional update)
He Youwei did not go back, but took a long leave from Union Hospital and temporarily lived in a small single-family villa in Hailufeng Company.
Considering that he was busy with work and that it was difficult for men and women to get along alone, Jiang Miao arranged for Shuya to take He Youwei with him.
Shuya is currently researching the Colonii Fungus. Thanks to the brain-strengthening diet and the genetic rules taught to her by Jiang Miao, her research on the Collinary Fungus has almost made rapid progress.
She has studied and understood the underlying mechanism of the symbiosis between Galliae fungus and termites. By imitating this symbiosis mechanism, Galliae fungus can be cultivated in a directional manner. The growth cycle is about 75 days, and the yield per mu can reach 3,000 to 4,000 kilograms.
At this time, Shuya finally understood where Jiang Miao's ability to quickly develop various technologies came from. She thought that Jiang Miao had this ability because he had mastered the laws of genes.
Considering the outside world's acceptance, Shuya did not immediately announce the related technologies and papers on the gallinobacteria, but still claimed to be studying morels.
Regarding He Youwei's situation, Jiang Miao also discussed with Shuya. Although he could not teach him all the genetic rules, 11 of them were relatively simple and did not involve genetic rules for brain enhancement and life extension, so they could still be taught to him. .
Inside the edible fungi laboratory.
He Youwei, already wearing protective clothing and a helmet, looked at the pig genetic sequence on the computer screen.
Shuya treats teaching tasks as a holiday: "Based on the rules of growth functional genes, you can judge which gene fragments may affect its growth."
He Youwei subconsciously wanted to lift her glasses, and then she touched the plastic mask in front of her before she realized. She carefully looked at the pig's genetic sequence, then picked up a small book, constantly recording relevant information, while also performing calculations and deductions.
He Youwei, who did not have photographic memory, could do research much slower than Shuya. Coupled with her lack of proficiency in genetic rules, her calculations were stumbling.
More than three hours later.
She just deduced 17 gene fragments related to growth, of which 6 gene fragments are in one group, and the other 5 genes are in another group. The remaining 6 gene fragments have not yet found the corresponding genome.
After lunch, she hurried to the laboratory again.
Using specific nutrients and drugs, we try to stimulate the function of these genomes in pig stem cells in a petri dish.
The drugs and nutrients she uses are common and can pass through the cell membrane and directly reach the chromosomes to act on the genetic sequence; or they can produce indirect compounds that act on the genetic sequence.
The afternoon passed without realizing it.
He Youwei's eyes became brighter and brighter.
Shuya took a look at the genome she selected: "The No. 3 gene fragment of this genome will increase the bone growth rate with the help of trace amounts of calcium and vitamin K. Do your stem cells show signs of transforming into bone cells?" < br>
"Ah... yes, Teacher Shuya." He Youwei was like a chicken pecking at rice: "Teacher, have you studied this?"
"No need to study, you haven't learned the third gene rule yet. If you learn this rule, you can know which gene fragments correspond to functional cells. This is the basic content in the process of inducing the transformation of stem cells into functional cells. You are familiar with it. Once you see the corresponding gene sequence, you will know its corresponding functional cell.”
"So that's it." He Youwei was thinking in her heart, what kind of foundation is this? Even experts who specialize in stem cell directional induction research probably don't know this kind of foundation.
At the same time, she also felt that Jiang Miao and his wife were both geniuses. Only after she studied a little bit did she realize how powerful their research was.
It can only be said that she knows nothing about sex.
In the next few days, He Youwei has been doing research in the laboratory with Shuya. As the content of her studies increases, she has become more and more comfortable in the application of those genetic laws.
But it's still not as good as Jiang Miao and Shuya, who have a photographic memory and master all genetic laws.
But even so, He Youwei felt as if she had opened up the Rendu lineage and entered a brand new biological world.
This made her feel like she couldn't stop, and at the same time she had firm confidence in treating her systemic lupus erythematosus.
Especially after learning the two genetic rules of immune system genes, she realized that it was not difficult to turn off part of the body's immunity.
During the experiment, under Shuya's guidance, she completely opened the immune system of pig stem cells into an indiscriminate attack mode, and then used drugs to stimulate several specific gene targets to gradually shut down the fully opened immune system. until it returns to normal levels.
If Shuya hadn't forbidden her to experiment on herself and asked her to do in vitro cell culture and research first, He Youwei might have been eager to try it on herself.
After all, the drugs used on pig stem cells are common ingredients extracted from several natural herbs and animals. Calculated based on body weight ratio, they do not reach toxic doses.
In fact, He Youwei also discovered that this method of treatment is not only very precise, but also uses relatively small doses of drugs.
For example, one of the organic macromolecules extracted from plantain has been tested on animals by other domestic scientific research institutions, and the toxic dose was 0.032 mg per kilogram of body weight.
However, when used on pig stem cells, the dose is only 0.0024 mg per kilogram of body weight, which is about one-fourth of the toxic dose.
The situation with other drugs used in combination is similar, that is, there is a lot of room for adjustment from the toxic dose.
Moreover, during the research process, He Youwei also discovered that the drugs, elements, vitamins, and nutrients that can act on these gene targets are often not one-to-one, but have multiple ingredients that can act on the same target. superior.
This brings another benefit, that is, you can choose an ingredient with relatively few side effects, thereby reducing the toxic side effects of the drug on the body.
The reason why other scientific research institutions have not found that these ingredients can be used for gene target therapy is mainly because some ingredients have no obvious effect when used alone, but must be used in combination.
This requires an in-depth study of Jiang Miao's genetic regulation system and a simultaneous understanding of various functional genomes, gene groups, and gene families, so that systematic combination of drugs can be used.
Otherwise, even eating a ton of plantains will be of no use, and you may be sent away by the toxic side effects.
It was the combination drug plan based on pig stem cells, and the dosage was within a safe and controllable range, that made He Youwei ready to take action. Fortunately, Shuya reminded her that there are differences in the genes of humans and pigs. What works for pigs may not necessarily work for pigs. People have the same effect.
at the same time.
In the past few days, Jiang Miao has also asked people to investigate whether there are any pharmaceutical companies suitable for acquisition.
After several days of searching, Business Secretary Liu Deming knocked on the door with a document.
"Boss, this is a listed company that is currently on the verge of bankruptcy or is poorly managed."
Jiang Miao opened the document and took a cursory look.
There are two companies in total, namely:
Yuanyuan Kang Pharmaceutical, the company submitted a listing application to the Hong Kong Stock Exchange last year, currently has no commercialized products. In 2022, 2023, 2024, and the first three quarters of 25, the cumulative loss is approximately 1.47 billion yuan, and the net debt is Reaching 1.271 billion yuan.
Its core product TY-9591 is a third-generation EGFR inhibitor. Although it has shown preliminary clinical efficacy, it has been trapped in the red sea before it was launched. There is also the risk of patent disputes. It was successfully launched in August last year and is now in a state of bankruptcy. edge.
Qiongzhou Haiyao's main business includes the research and development, production and sales of drugs and medical devices. The 2024 financial report shows that the total operating income was 925 million yuan, a year-on-year decrease of 42.36%, and the net profit loss attributable to the parent company was 350 million yuan, excluding non-net profit losses. 220 million yuan.
The company has performed poorly in recent years and is facing greater operating pressure and financial difficulties. Its R&D investment may be restricted, which will affect the advancement of its pharmaceutical and medical device R&D projects.
Jiang Miao directly crossed out Qiongzhou Haiyao. This kind of company is too troublesome, and its size is not small, and the acquisition funds are too much.
On the contrary, Yuanyuankang Pharmaceutical, which is on the verge of bankruptcy, can consider acquisition. If debt is included, it should be worth about 3 billion.
However, after he opened up the details of Yuanyuankang Pharmaceutical, he felt that this company would also be difficult to handle.
Because the founder of this company is a senior practitioner in three pharmaceutical industries. He is either a Ph.D. in the field of pharmaceutical research and development or an expert in drug development and clinical trials. Such people will not sell the company easily.
Moreover, the company has a complete industrial chain. It has established R&D centers and production bases in Hucheng, Magic City, Zhejiang Province, and Shangdu, Central Plains Province, etc., and has drug R&D and production capabilities.
This means that the other party will not let go easily.
At this moment, Li Jianming made a call.
"Amiao, have you found a suitable pharmaceutical company?"
"Not yet."
"I have a friend here who wants to sell a pharmaceutical company. He acquired a small pharmaceutical company in Yangcheng a few years ago, but the business turned out to be very poor."
"Are the documents and procedures complete?" "They are complete. The R&D and production procedures for drugs and medical devices are complete. There are also two factories, one that produces ibuprofen and the other that produces masks and protective clothing."
"How much did he quote?"
"The factory is located on the outskirts of Conghua District in the northeast of Yangcheng. It includes the land and office buildings of the two factories, plus the production line and related certificates and access qualifications. He wants 200 million."
"You send me the information on WeChat, and then I will send someone to investigate the specific situation."
"Okay."
After a while, Li Jianming sent the relevant information.
Jiang Miao took a look.
This company is called "Xinlekang Pharmaceutical".
With the name and shareholder information, for Jiang Miao, it is basically equivalent to information transparency.
He asked the business secretary Liu Deming to go out.
Then use the Internet to quickly dig out all the information about the company and its shareholders.
After reading the relevant information, Jiang Miao already understood the specific situation of this company. It was indeed poorly run. The major shareholder was not a professional. After acquiring this pharmaceutical company in 2017, he was deceived into developing an anti-aging drug. After investing 500 million, he realized that he had been deceived, and the person who had deceived him had already fled to Maple Leaf Country with his whole family.
If he hadn't made a fortune on ibuprofen, masks, and protective clothing in the past few years, he would probably be ashamed of himself.
In the past two years, with the decline in market demand, Xinlekang Pharmaceutical was once again brought back to its original shape. Seeing that the company was already struggling, this person also learned from the pain and prepared to sell the company.
However, after the news was released, no one cared about it.
In fact, this is normal. After all, domestic large and Chinese pharmaceutical companies look down upon such small pharmaceutical companies. Small pharmaceutical companies cannot protect themselves, and other lay investors are also discouraged from the pharmaceutical industry.
It wasn't until Jiang Miao said he wanted to acquire a pharmaceutical company a few days ago that Li Jianming remembered the pharmaceutical company his friend wanted to sell, and planned to make a matchmaking connection and make a smooth favor.
Jiang Miao took a look. Although Xinlekang Pharmaceutical only has two factories, the ibuprofen factory also has a pharmaceutical research and development laboratory, which was previously invested to develop new drugs. The instruments and equipment inside are worth about 80 million. This It is also the most valuable thing of the company besides the office building and the set of certificate procedures.
As for the other ibuprofen production lines, mask production lines and protective clothing production lines, they are not worth 5 million in total. After all, this is third-hand equipment.
Even the value of the two pieces of industrial land is not very high. The total 96 acres of land, including the factory building, is worth 90 million; the office building is worth about 27 million.
As for laboratory equipment and factory equipment, it is estimated that the other party also knows that these second-hand goods are difficult to get a high price.
Therefore, a total price of 200 million was quoted.
The price was nothing, and it was within Jiang Miao's acceptance range. He then packaged some of the information that could be collected from the surface Internet and sent it to Commercial Secretary Liu Deming, asking him to instruct the purchasing department to send someone to inspect Xinlekang Pharmaceutical Company.
Regarding the positioning of a pharmaceutical company, Jiang Miao only plans to set up a joint-stock limited company, name himself a chairman, and then recruit a professional manager to serve as CEO, plus He Youwei as chief technology executive.
He does not plan to keep any more shares in this company. Some people who need to join can be brought into this company.
However, he, Shuya and He Youwei will set up a joint-stock company to spin off the pharmaceutical company's R&D business and sell it to this company. Then they will register all relevant patents under the name of this company and license them to the pharmaceutical company on a regular basis. It is free to use, and the technology is licensed to pharmaceutical companies on an annual basis.
In this way, even if Jiang Miao and He Youwei do not occupy the majority of the shares of the pharmaceutical company, they can still firmly control the pharmaceutical company.
In order to maximize profits, we can even license technology to many domestic pharmaceutical companies.
Jiang Miao himself only plans to focus on the agricultural industry. Maybe Shuya can develop in medicinal fungi in the future, but that will happen in the future.
Therefore, he has a completely dispensable attitude towards pharmaceutical companies. After all, if he and his family need drugs, they can secretly synthesize some in his own laboratory.
After the pharmaceutical company is established, Jiang Miao will not hand over too many technologies to the company. After all, many technologies are too sensitive.
For example, through genetic rules, he uses specific drugs to act on corresponding gene targets, which can effectively inhibit telomere shortening, thereby delaying aging to a certain extent and extending life span by about ten years.
If this technology were released now, Jiang Miao would definitely become the target of public criticism.
Another example is his brain-strengthening diet plan. If this technology becomes known, it may trigger a world war.
Therefore, the technology that can be licensed to pharmaceutical companies will most likely be similar to drugs used to treat systemic lupus erythematosus, such as the treatment of special allergies, infertility, Alzheimer's disease, hyperlipidemia, hypertension, hyperglycemia, Drugs for high uric acid, various cancers and the like.
The direction of extending life span and enhancing brain power is an absolute taboo.
Before I knew it, it was the 6th.
Yang Hejun, chairman of Chengyi Group, came with five employees.
"Senior Brother Yang, hello!"
"Junior Brother Jiang Miao, I'm sorry to bother you, please be careful." Yang Hejun smiled and handed him a few bags.
Jiang Miao could only accept it, and then led the other party into his temporary office.
Tea has been brewed in advance in the office.
After sitting down, Jiang Miao poured tea for the other party and asked with a smile: "Brother, I'm here this time. It just so happened that the dock caught a few wild groupers today. Let's try something new at noon."
"Junior brother, you are too polite." Yang Hejun took a sip of tea, shook his head and joked: "Junior brother, your company will probably surpass mine soon, and you won't be able to do that even if you don't accept it!"
< br>
"Haha, it just happened to happen."
"Hey, junior brother, you are being humble. Without skills, no matter how many opportunities you have, it will be in vain." Yang Hejun then changed his tone: "Junior brother, I came to visit this time mainly to see if I can cooperate with your company."
"Senior brother, it doesn't matter." Jiang Miao gave the other party some more tea.
"Then let me tell you straight, Junior Brother Jiang, I want to cooperate with your company to develop feed that can shorten the breeding cycle of grass carp. I have learned about your company's eel feed and Egyptian pond lice feed, which can effectively shorten the breeding cycle or improve growth. Speed." Yang Hejun had actually learned about the relevant situation of Hailufeng Company before coming here.
Especially after learning that Jiang Miao graduated from Shizishan Agricultural University, he quickly entrusted Shizishan Agricultural University to help with the matchmaking.
"Grass carp feed?" Jiang Miao also knew about Chengyi Group's business. The other party has a 16,000-acre breeding base for grass carp breeding.
When grass carp is intensively cultured, it usually takes about 1.5 to 2 years before it can be sold.
Such a long breeding cycle will not only cause breeding costs to soar, but will also increase uncontrollable risks and lengthen the capital return cycle.
Yang Hejun was also shocked when he saw that Jiang Miao could shorten the eel breeding cycle from more than a year to seven months.
"Brother, in fact, our company has reached an agreement with Haid Group before. In the future, we will successively develop customized feeds made from Egyptian pond lice meal. Of course, this agreement does not have exclusivity clauses. Therefore, if our company successfully develops grass carp-related feed formulas, , and can also be licensed to Chengyi Group for use. ”
Hearing this, Yang Hejun was also surprised.
Of course, he knew about Haid Group. After all, they were both companies in Yangcheng, Lingnan, and the two sides still had overlapping businesses.
Chengyi Group also produces feed, but their company generally produces and sells it on its own, with an annual output of about 40,000 to 60,000 tons.
"In that case, I won't force it." Yang Hejun said another thing:
"Junior Brother Jiang, do you know if the technology related to Egyptian pond lice fish meal can be licensed to our company?"
Jiang Miao shook his head: "Brother, you might as well purchase directly from Haid Group. Their Egyptian pond lice meal will be mass-produced next year. Anyway, your grass carp breeding cycle is relatively long. You can first use the feed made from Egyptian pond lice meal." For the rest of the year, switch to other feeds and add a running pool, which can effectively reduce the earthy smell. ”
After Jiang Miao's explanation, Yang Hejun also gave up the idea of breeding Egyptian fish himself, and planned to purchase it from Haid Group when the Egyptian fish meal is produced next year.
(End of chapter)